Cancer care company spreads wings to China
MELBOURNE: Medical tourism is the fastest growing segment in both the tourism and healthcare sectors.
Australia’s largest cancer care company, Brisbane-based Icon, is moving to take advantage of the medical tourism business from mainland China with a purchase of an oncology practice in Hong Kong.
Icon, which is owned by a consortium including the Queensland Investment Corporation, Goldman Sachs Private Equity and Chinese private equity fund Pagoda Investment, announced on Wednesday it would be buying Hong Kong-based SunTech Medical.
“Hong Kong’s cancer spend is expected to nearly double from $2.45bn to more than $4.5bn by 2026 due to an ageing population and an increase in medical tourism from mainland China,” Icon chief executive Mark Middleton said.
“We see an opportunity to complement existing cancer care providers by increasing capacity in the market to meet this growing demand.”
Mr Middleton said Icon had been looking to get into the Hong Kong market since it announced its expansion into Asia three years ago but had been waiting for the right opportunity.
Icon, which has more than 20 cancer care centres and more than 60 pharmacies specialising in the drugs needed for cancer treatment in Australia, expanded into Singapore in 2016 when it bought four chemotherapy day centres.
It has since increased these to seven. The number of doctors working with the company in Singapore has risen from three to 11 in the past three years.
SunTech has four clinics in Hong Kong — two in Kowloon and two on Hong Kong Island — and four doctors.
Mr Middleton said Icon had been watching the situation in Hong Kong closely with protesters demonstrating in the city’s streets over the past three months against planned changes to legislation to allow people in Hong Kong accused of breaking Chinese law to be extradited to mainland China.
But he said he did not expect the current situation to affect demand for specialist health care in Hong Kong.
“Regardless of the volatility, people still require healthcare and oncology care,” he said.
“Our doctors are really busy in Hong Kong and we want to help them achieve their vision to help more people with cancer.”
Hong Kong is a popular city for people from southern China to travel for specialist medical treatment.
“We see SunTech as providing a platform for further growth in Asia and into mainland China,” he said.
There were already plans to expand the Hong Kong business by hiring more doctors.
Mr Middleton said that Icon now had 20 per cent of its business outside Australia.
He said expansion plans in Hong Kong and China would mean the company had 30 to 40 per cent of its business outside Australia, including 20 per cent from Hong Kong and China.
The Hong Kong deal follows one announced in June to deliver cancer radiation services to a hospital group in Qingdao in the China coast, owned by China’s United Family Healthcare.
The company also had an agreement to deliver anti-cancer radiation services at a hospital in the western city of Chongqing with Sanbo Hospital Group.
Icon was valued at more than $1 billion in a deal announced in late 2017 when the group was sold to the QIC-led consortium by Quadrant Private Equity.







